Search

Displaying results 3441 - 3450 of 8412 in total
  1. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  2. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond....

  3. Drug

    Chlormerodrin Hg-197

    go.drugbank.com/drugs/DB09406
    Approved

    Chlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.

  4. Drug

    Bexarotene

    go.drugbank.com/drugs/DB00307
    ApprovedInvestigational

    Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
  5. Drug

    Propantheline

    go.drugbank.com/drugs/DB00782
    Approved

    A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

  6. Drug

    Clobetasol

    go.drugbank.com/drugs/DB11750
    ApprovedInvestigationalWithdrawn

    Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  7. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the F...

  8. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  9. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes. … Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  10. Drug

    Cobalt

    go.drugbank.com/drugs/DB14574
    ApprovedWithdrawn

    Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.